Aligos Therapeutics (ALGS) EPS (Basic) Growth (3y) (2022 - 2026)
Aligos Therapeutics (ALGS) EPS (Basic) Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | -38.31% |
| 10 | Aligos Therapeutics | 69.89 Mn | 39.44 Mn | - | 30.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.33% |
| Mar 31, 2026 | 45.09% |
| Dec 31, 2025 | 46.06% |
| Sep 30, 2025 | 34.63% |
| Jun 30, 2025 | 49.18% |
| Mar 31, 2025 | 30.93% |
| Dec 31, 2024 | 17.85% |
| Sep 30, 2024 | 46.03% |
| Jun 30, 2024 | 26.84% |
| Mar 31, 2024 | 32.91% |
| Dec 31, 2023 | 49.87% |
| Sep 30, 2023 | 66.46% |
| Jun 30, 2023 | 61.12% |
| Mar 31, 2023 | 58.64% |
| Dec 31, 2022 | 61.55% |
| Sep 30, 2022 | 59.87% |